SCHEMBL6487952

SCHEMBL6487952

O=C(N[C@@H]1C[C@H]2CCN(C2)C1)c1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 11/20 0.54
NPC1 O15118 7/20 0.54
LMNA P02545 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
NPSR1 Q6W5P4 2/20 0.54
GAA P10253 1/20 0.54
HTT P42858 1/20 0.54
CHRNA7 P36544 2/20 0.54
CASP3 P42574 2/20 0.50
SENP7 Q9BQF6 2/20 0.50
MAPT P10636 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MAPK1 P28482 1/20 0.50
RECQL P46063 1/20 0.50
SENP8 Q96LD8 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
ALDH1A1 P00352 2/20 0.49
HPGD P15428 1/20 0.49
MAPKAPK2 P49137 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6487956 1.00 RAB9A (0.54) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6501599 0.88 CHRNA7 (0.49) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6501606 0.88 CHRNA7 (0.49) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6496459 0.87 RAB9A (0.51) RAB9ANPC1SMN1; SMN2GAACHRNA7
SCHEMBL6492453 0.87 CHRNA7 (0.48) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6497050 0.87 ALDH1A1 (0.51) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6497048 0.87 ALDH1A1 (0.51) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6492457 0.87 CHRNA7 (0.48) RAB9ANPC1LMNASMN1; SMN2NPSR1
SCHEMBL6496455 0.87 RAB9A (0.51) RAB9ANPC1SMN1; SMN2GAACHRNA7
Hydrochloric Acid SCHEMBL6501240 0.86 RAB9A (0.50) RAB9ANPC1SMN1; SMN2GAACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 RAB9A 1437/4885NPC1 224/4885LMNA 2990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.